Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients
- 27 March 2010
- journal article
- other
- Published by Wolters Kluwer Health in AIDS
- Vol. 24 (6) , 931-932
- https://doi.org/10.1097/qad.0b013e3283319954
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of RaltegravirAntimicrobial Agents and Chemotherapy, 2009
- An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected PatientsTherapeutic Drug Monitoring, 2008
- Raltegravir: The first HIV integrase inhibitorClinical Therapeutics, 2008
- Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System PharmacotherapyPharmacological Reviews, 2008
- Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous SystemArchives of Neurology, 2008
- HPLC–MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patientsJournal of Chromatography B, 2007
- Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase EnzymeDrug Metabolism and Disposition, 2007
- Antiretroviral drugs and the central nervous systemAIDS, 1998